Mostrar el registro sencillo

dc.contributor.authorMontcel, Sophie Tezenas du
dc.contributor.authorDurr, Alexandra
dc.contributor.authorRakowicz, Maria
dc.contributor.authorNanetti, Lorenzo
dc.contributor.authorCharles, Perrine
dc.contributor.authorSulek, Anna
dc.contributor.authorMariotti, Caterina
dc.contributor.authorRola, Rafal
dc.contributor.authorSchols, Ludger
dc.contributor.authorBauer, Peter
dc.contributor.authorDufaure-Garé, Isabelle
dc.contributor.authorJacobi, Heike
dc.contributor.authorForlani, Sylvie
dc.contributor.authorSchmitz-Hübsch, Tanja
dc.contributor.authorFilla, Alessandro
dc.contributor.authorTimmann, Dagmar
dc.contributor.authorWarrenburg, Bart P., van de
dc.contributor.authorMarelli, Cecila
dc.contributor.authorBerciano, José Ángel 
dc.contributor.authorInfante Ceberio, Jon 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-03-22T11:09:59Z
dc.date.available2024-03-22T11:09:59Z
dc.date.issued2014
dc.identifier.issn0022-2593
dc.identifier.issn1468-6244
dc.identifier.urihttps://hdl.handle.net/10902/32402
dc.description.abstractBackground: The most common spinocerebellar ataxias (SCA)—SCA1, SCA2, SCA3, and SCA6—are caused by (CAG)n repeat expansion. While the number of repeats of the coding (CAG)n expansions is correlated with the age at onset, there are no appropriate models that include both affected and preclinical carriers allowing for the prediction of age at onset. Methods: We combined data from two major European cohorts of SCA1, SCA2, SCA3, and SCA6 mutation carriers: 1187 affected individuals from the EUROSCA registry and 123 preclinical individuals from the RISCA cohort. For each SCA genotype, a regression model was fitted using a log-normal distribution for age at onset with the repeat length of the alleles as covariates. From these models, we calculated expected age at onset from birth and conditionally that this age is greater than the current age. Results: For SCA2 and SCA3 genotypes, the expanded allele was a significant predictor of age at onset (−0.105±0.005 and −0.056±0.003) while for SCA1 and SCA6 genotypes both the size of the expanded and normal alleles were significant (expanded: −0.049±0.002 and −0.090±0.009, respectively; normal: +0.013±0.005 and −0.029±0.010, respectively). According to the model, we indicated the median values (90% critical region) and the expectancy (SD) of the predicted age at onset for each SCA genotype according to the CAG repeat size and current age. Conclusions: These estimations can be valuable in clinical and research. However, results need to be confirmed in other independent cohorts and in future longitudinal studies.es_ES
dc.description.sponsorshipThis study was supported by grants EUROSCA/LSHM-CT-2004-503304 from the European Union, grant from the European Community's Seventh Framework Programme (FP7/2007-2013 n° 2012-305121 NEUROMICS), GeneMove/01 GM 0503 from the German Ministry of Education and Research, within the framework of the ERA-Net for Research Programmes on Rare Diseases, grant 3 PO5B 019 24 from the Polish Ministry of Scientific Research and Information Technology, and grant No 674N—RISCA/2010—2014 from Polish Ministry of Science and Higher Education. The research leading to these results has received funding from the programme ‘Investissements d'avenir’ ANR-10-IAIHU-06. BPvdW is supported by research grants from the Netherlands Brain Foundation, the Royal Dutch Society for Physical Therapy, BBMRI-NL, and the Radboud University Medical Centre. MB is supported by the grant OTKA K 103983. AF was supported by a grant from POR CREME 2007-20013. AB was supported by the grant EUROSCA/LSHM-CT-2004-503304 and by the grant NEUROMICS (7th framework programme) from the European Union. AB, AD and GS received funding from the VERUM Foundation. AD received support from ANR (French Research Agency) and Eranet for the Risca project, PG and AC work at University College London Hospitals/University College London which receives a proportion of its funding from the Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme. Paola Giunti receives funding from the EC (HEALTH-F2-2010-242193; FP7 Grant). DeNDRoN, Ataxia UK and NIHR, Department of Health.es_ES
dc.format.extent9 p.es_ES
dc.language.isoenges_ES
dc.publisherBMJ Publishing Groupes_ES
dc.rightsAtribución-NoComercial 3.0 Españaes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.sourceJournal of Medical Genetics, 2014, 51(7), 479-480es_ES
dc.titlePrediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1136/jmedgenet-2013-102200es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1136/jmedgenet-2013-102200
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Atribución-NoComercial 3.0 EspañaExcepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial 3.0 España